Success Metrics

Completion Rate
0%(0/4)
Active Trials
0(0%)
Terminated
4(100%)

Phase Distribution

Ph phase_1
4
100%

Phase Distribution

4

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
4(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 4 finished

Non-Completion Rate

100.0%

4 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Terminated(4)

Detailed Status

Terminated4

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
0.0%
Most Advanced
Phase 1

Trials by Phase

Phase 14 (100.0%)

Trials by Status

terminated4100%

Recent Activity

0 active trials
Showing 4 of 4
terminatedphase_1

An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies

NCT02712905
terminatedphase_1

A Study of INCB059872 in Relapsed or Refractory Ewing Sarcoma

NCT03514407
terminatedphase_1

Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)

NCT02959437
terminatedphase_1

A Study to Evaluate Safety, Pharmacokinetic, and Biological Activity of INCB059872 in Subjects With Sickle Cell Disease

NCT03132324

Clinical Trials (4)

Showing 4 of 4 trials
NCT02712905Phase 1

An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies

Terminated
NCT03514407Phase 1

A Study of INCB059872 in Relapsed or Refractory Ewing Sarcoma

Terminated
NCT02959437Phase 1

Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)

Terminated
NCT03132324Phase 1

A Study to Evaluate Safety, Pharmacokinetic, and Biological Activity of INCB059872 in Subjects With Sickle Cell Disease

Terminated

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4